Prostate最新文献

{"title":"MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells.","authors":"Changying Li, Chenchen He, Jiancheng Pan, Yuhong Feng, Dawei Tian, Jinhuan Meng, Zhi Qi, Changlin Li, Kuo Yang","doi":"10.1002/pros.70053","DOIUrl":"https://doi.org/10.1002/pros.70053","url":null,"abstract":"<p><strong>Objective: </strong>Androgen deprivation therapy (ADT) was the frontline treatment for patients with prostate cancer ineligible for radical prostatectomy. However, the development of resistance to ADT significantly limits its clinical efficacy.</p><p><strong>Methods: </strong>Using a genome-wide CRISPR/Cas9 knockout (GeCKO) library screen combined with single-cell RNA sequencing (scRNA-seq) analysis, we identified key genes involved in ADT resistance.</p><p><strong>Results: </strong>Macrophage migration inhibitory factor (MIF) was identified as a critical mediator of ADT resistance. Inhibition of MIF significantly overcomes ADT resistance. Moreover, we found that the androgen receptor (AR), but not its splice variant AR-V7, negatively regulates MIF expression. Consequently, inhibition of the AR signaling pathway via ADT results in the upregulation of MIF expression. Elevated expression of MIF promotes prostate cancer cell proliferation by upregulating AMPD2 expression.</p><p><strong>Conclusions: </strong>Our findings demonstrate that ADT induces MIF upregulation, which in turn drives prostate cancer cell proliferation via upregulating AMPD2 expression, eventually contributing to the development of resistance to ADT.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy.","authors":"Kambiz Rahbar, R David Rosin, Mark Kidd, Abdel B Halim, Oliver Sartor","doi":"10.1002/pros.70052","DOIUrl":"https://doi.org/10.1002/pros.70052","url":null,"abstract":"<p><strong>Background: </strong>Prostate-specific antigen (PSA) remains the standard biomarker for prostate cancer (PCa) detection, but its limited specificity-particularly in the 3-10 ng/mL range-leads to overdiagnosis and unnecessary biopsies. Including multiparameteric MRI (mpMRI) helps to reduce the number of PSA-false-positive biopsies, but there is still a need for noninvasive diagnostics that improve risk stratification and reduce unnecessary interventions.</p><p><strong>Methods: </strong>PROSTest is a peripheral blood-based assay that quantifies a 27-gene signature in the androgen receptor (AR) signaling pathway in addition to 3 housekeeping genes (HKGs). PCR results are fed into a proprietary machine learning (ML) algorithm to produce a numerical score on a scale of 0-100 with a clinically validated cutoff of 50 for a final binary readout; positive or negative for likelihood of cancer on biopsy. In this report, the diagnostic performance of PROSTest was evaluated in 1,894 male subjects including 970 individuals with actionable results (PSA ≥ 3.0 ng/mL). We focused on two PSA-graded intended-use populations: subjects aged ≥ 45 years with PSA 3-10 ng/mL (n = 467), and those with PSA > 10 ng/mL (n = 503). PSA and PROSTest were conducted on all subjects.</p><p><strong>Results: </strong>In the 970 cohort, adding the PROSTest achieved an AUC of 0.96 and was significantly more accurate than PSA alone for differentiating PCa from benign prostatic disease (Chi² = 134.1, p < 0.0001). In the 467 subjects with PSA 3-10 ng/mL, the PROSTest achieved an AUC of 0.94, with 94% sensitivity and 91% specificity. The PPV for PROSTest was 91.6% (95%CI: 88.3-94.1%) and NPV was 95.6% (95%CI: 91.6-97.7%). The blood-based gene expression profiling correctly identified 435 of 467 subjects (93.1%) and was significantly more accurate than PSA alone where only 271 of 467 (58.0%) with high PSA had PCa (Chi² = 155.9, p < 0.0001). The sensitivity of the assay for detecting PCa was 97.0% (263/271). In the 503 subjects with PSA > 10 ng/mL, PROSTest yielded an AUC of 0.93 versus 0.76 for PSA (z = 5.3, p < 0.0001). Despite the very high levels of PSA ( > 10 g/mL), 63 (20 BPH and 43 non-BPH controls) out of the 503 (12.5%) subjects were negative for PCa. PROSTest sensitivity was 93.6% (412/440) and the accuracy was 92.8% (467/503). The PPV for PROSTest was 98.1% (95%CI: 96.4-99.0%) and NPV was 66.3% (95%CI: 57.6-74.0%). If PROSTest was used, it would have precluded 55 of the 63 (87.5%) PSA-falsely driven biopsies.</p><p><strong>Conclusions: </strong>PROSTest demonstrates improved stratification value relative to PSA and could significantly reduce PSA-driven false positive biopsies. Out of 259 non-PCa subjects biopsied based on high PSA levels, applying PROSTest could potentially eliminate 227 biopsies (87.6%). PROSTest superior NPV was not confounded as a tradeoff for the PPV as PROSTest exhibited a sensitivity of ~95% (675/711 PCa detected).</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Resveratrol Inhibits the Tumor Migration and Invasion by Upregulating TET1 and Reducing TIMP2/3 Methylation In Prostate Carcinoma Cells\".","authors":"","doi":"10.1002/pros.70047","DOIUrl":"https://doi.org/10.1002/pros.70047","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.","authors":"Trevor C Hunt, Kamil Malshy, Matthew Steidle, Ashley Li, Jason Fairbourn, Zijing Cheng, Jathin Bandari","doi":"10.1002/pros.70043","DOIUrl":"https://doi.org/10.1002/pros.70043","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is the only cancer in men to exhibit androgen sensitivity at diagnosis, which has allowed for the development of androgen deprivation therapy (ADT). However, outcomes in high-risk PCa (HRPCa) remain significantly worse than low risk disease and the use of ADT varies among treatment algorithms and medical specialties. In men treated with radiation, testosterone recovery after completing ADT has been associated with oncologic outcomes. However, the relationship between testosterone recovery and oncologic outcomes following ADT in surgically managed HRPCa remains unexplored.</p><p><strong>Methods: </strong>Using pooled data from two large, phase III clinical trials (CALGB 90203 and SWOG S9921), we performed a retrospective analysis of men with HRPCa treated with ADT and RP. Subjects were classified as recovered or non-recovered based on study protocol-defined testosterone recovery thresholds. Primary and secondary outcomes were overall survival (OS) and modified event-free survival (mEFS), analysed utilizing time-to-event Kaplan-Meier estimates and Cox proportional hazards models. Additional secondary analyses repeated this on an unpooled, per trial basis and also looked at speed of testosterone recovery using early ( ≤ 6 months) and late ( ≤ 12 months, including early recoverees) recovery subgroups.</p><p><strong>Results: </strong>Among 445 eligible patients meeting our inclusion criteria, 87.2% achieved testosterone recovery. No significant differences in OS (HR = 0.72, p = 0.400) or mEFS (HR = 1.24, p = 0.360) were observed between the recovered and non-recovered groups. Similarly, no significant differences were present when OS and mEFS were analysed separately in each individual trial's cohort. Finally, we also saw no differences in oncologic outcomes between the early and late testosterone recovery subgroups.</p><p><strong>Conclusions: </strong>Testosterone recovery status and speed were not significantly associated with oncologic outcomes in HRPCa patients treated with RP and ADT. These findings, the first to assess this question in a surgical cohort, provide a foundation for further research into treatment strategies, including intermittent ADT, and optimization of patient quality of life while maintaining oncologic efficacy.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific Mortality in Localized Prostate Cancer.","authors":"Fabian Falkenbach, Francesco Di Bello, Natali Rodriguez Peñaranda, Mattia Longoni, Andrea Marmiroli, Quynh Chi Le, Zhe Tian, Jordan A Goyal, Nicola Longo, Salvatore Micali, Alberto Briganti, Ottavio De Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Lars Budäus, Markus Graefen, Pierre I Karakiewicz","doi":"10.1002/pros.70045","DOIUrl":"https://doi.org/10.1002/pros.70045","url":null,"abstract":"<p><strong>Background: </strong>The USPSTF recommendation against PSA screening (RAPS) in 2012 resulted in unfavorable changes in prostate cancer (PCa) outcomes. However, the effect on cancer-specific mortality (CSM) in localized PCa has not been assessed.</p><p><strong>Methods: </strong>Within the Surveillance, Epidemiology, and End Results database (2004-2021), we identified patients treated with radiotherapy (RT) or radical prostatectomy (RP) for localized PCa. Time trends were examined using least-squares linear regression. Multivariable Cox regression was used to study the association between RAPS and PCa-mortality.</p><p><strong>Results: </strong>Of 270,092 patients aged < 75 years, 191,621 (70.1%) were treated before and 78,471 (29.1%) in the RAPS era. CSM at 6 years of follow-up was 1.6% (95% confidence interval [CI]: 1.6, 1.7) before and 1.9% (95%CI: 1.8, 2.0) in the RAPS era (p < 0.001). In multivariable Cox models adjusted to patient characteristics, RAPS era independently predicted 1.2-fold higher CSM overall (95%CI: 1.1, 1.3; p < 0.001), 1.3-fold higher CSM in RP-patients (95%CI: 1.1, 1.4; p < 0.001), and 1.1-fold higher CSM in RT-patients (95%CI: 1.02, 1.2; p = 0.02) aged < 75 years. Of 33,688 patients aged ≥ 75 years, 12,485 (37.1%) were treated before and 21,203 (62.9%) in the RAPS era. CSM at 6 years of follow-up was 4.2% (95%CI: 3.8, 4.6) before and 4.8% (95%CI: 4.5, 5.1) in the RAPS era (p = 0.002). In multivariable Cox models adjusted to patient characteristics, RAPS era did not predict higher CSM overall, in RP-patients, or in RT-patients (all p ≥ 0.5) aged ≥ 75 years. Limitations include changes in early detection and disease management over time, which might have impacted CSM as well.</p><p><strong>Conclusions: </strong>The USPSTF RAPS introduction resulted in a 1.2-fold higher CSM in localized PCa patients aged < 75 years, but not in patients aged ≥ 75 years. The time trend analysis suggested that this negative effect has become increasingly pronounced since the USPSTF RAPS.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Diagnostic Accuracy in Prostate Oncology: A Multidimensional Perspective on Prostate Specific Antigen Density.","authors":"Shengyi Chen, Yuekun Fang, Bin Cheng","doi":"10.1002/pros.70044","DOIUrl":"https://doi.org/10.1002/pros.70044","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.","authors":"Christian Andrés Martínez Osorio, Raquel Sopeña Sutil, Antoni Vilaseca Cabo, Estefanía Linares Espinós, Miguel Ramírez Backhaus, Juan Gómez Rivas, Marc Costa Planells, Sara Martinez Breijo, Natalia Picola Brau, Natalia Domínguez Esteban, Jesús Muñoz Rodríguez, Angeles Sanchís Bonet, Ana Guijarro Cascales, Manel Beamud Cortés, Pol Servian Vives, José Manuel de la Morena Gallego, Meritxell Pérez Márquez, Miguel García Sanz, José Ramón Alemán, Álvaro Zamora Horcajada, Victor Rodríguez Part, Mario Hassi Roman, Cristian Rodriguez Concha, Emilio Rios González, Pedro de Pablos-Rodríguez","doi":"10.1002/pros.70040","DOIUrl":"https://doi.org/10.1002/pros.70040","url":null,"abstract":"<p><strong>Background: </strong>PSA response to apalutamide combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) has been linked to prognosis. Post hoc analyses from clinical trials suggest that PSA levels at 6 months are critical for predicting radiographic progression-free survival (rPFS) and overall survival (OS). Real-world evidence (RWE) is needed to confirm these findings.</p><p><strong>Materials and methods: </strong>This multicentre, retrospective study included patients with mHSPC treated with apalutamide plus ADT from May 2018 to January 2025 across 18 Spanish centers. Patients were stratified according to PSA level at 6 months: Complete response (CR; ≤ 0.2 ng/mL) or incomplete response (IR; > 0.2 ng/mL). The primary objective was to evaluate the association between PSA response and rPFS at 24 and 36 months. Univariate and multivariate Cox regression analyses were used to identify predictors of progression.</p><p><strong>Results: </strong>Among 812 patients, 65% achieved a CR at 6 months, associated with higher rPFS at 24 (94%) and 36 (81%) months compared to the IR group (73% and 60%, respectively; p < 0.0001). CR (hazard ratio: 0.38; p < 0.001) and low-volume disease (hazard ratio: 0.41; p < 0.001) were independent predictors of rPFS. Baseline PSA, disease volume, and positron emission tomography imaging predicted achieving a CR.</p><p><strong>Conclusions: </strong>In this large real-world cohort, PSA response at 6 months was a strong predictor of disease progression, supporting its use as a dynamic prognostic biomarker.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Transperineal Drainage for Treating Prostatic Abscess: A Comparative Analysis Against Conservative Management.","authors":"Sung Goo Yoon, Tae Il Noh, Ji Sung Shim, Min Gu Park, Seok Ho Kang, Sung Gu Kang","doi":"10.1002/pros.24922","DOIUrl":"10.1002/pros.24922","url":null,"abstract":"<p><strong>Background: </strong>Prostatic abscess (PA) is an uncommon but serious urological condition requiring immediate intervention. Both drainage and conservative treatment are feasible because there are currently no well-established treatment guidelines. This study aimed to compare the clinical outcomes and mortality rates between patients who underwent transperineal prostatic abscess drainage (TPAD) and those who underwent conservative management.</p><p><strong>Methods: </strong>We analyzed 41 patients diagnosed with PA using computed tomography, magnetic resonance imaging, and transrectal ultrasonography between December 2021 and July 2024. The patients underwent either TPAD or conservative management. Conservative management consisted of intravenous antibiotics as the mainstay of therapy, whereas the intervention group received TPAD in addition to antibiotic therapy. TPAD was performed under local anesthesia with the patient in the lithotomy position. All patients were discharged after the normalization of inflammatory markers and body temperature.</p><p><strong>Results: </strong>Of the initial total of 41 patients, 6 were excluded based on the exclusion criteria. Among the remaining 35 enrolled patients, 18 underwent TPAD and 17 received conservative management. There were no significant differences in age, number of comorbidities, or prostate-specific antigen levels between the two groups; however, the TPAD group exhibited a significantly larger abscess size (p = 0.000), shorter hospital stay (p = 0.041), and lower mortality (p = 0.045).</p><p><strong>Conclusions: </strong>In the absence of standardized treatment guidelines, TPAD which can be easily implemented, is considered a favorable treatment method that can reduce the length of hospital stay, recurrence rates, and mortality rates compared with conservative treatment.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1161-1167"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.","authors":"András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas","doi":"10.1002/pros.24923","DOIUrl":"10.1002/pros.24923","url":null,"abstract":"<p><strong>Background: </strong>While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.</p><p><strong>Methods: </strong>A large, country-wide health insurance database (2013-2023) was assessed for the OS comparison between abiraterone and enzalutamide.</p><p><strong>Results: </strong>Overall, 3497 patients were identified with first- (n = 2215) or second-line (n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide-treated patients had longer OS both in the first- (HR:0.84; 95%CI:0.74-0.96; p = 0.008) and the second-line setting (HR:0.88; 95%CI:0.78-0.99; p = 0.043), respectively.</p><p><strong>Conclusions: </strong>This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1151-1154"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.","authors":"Yuanchu J Yang, Chenjie Zeng, Kerry R Schaffer, Tam C Tran, Peter J Sauer, Lincoln A Brown, Ben H Park, Joshua C Denny","doi":"10.1002/pros.24913","DOIUrl":"10.1002/pros.24913","url":null,"abstract":"<p><strong>Background: </strong>Hormone therapy (HT) has greatly improved overall survival for prostate cancer patients, but may also influence cardiovascular health in an already high-risk population.</p><p><strong>Methods: </strong>This retrospective cohort study examined participants in the All of Us Research Program with prostate cancer, had no prior history of adverse cardiovascular events, and were either treated or not treated with HT. HT was defined as GnRH agonists, GnRH antagonists, abiraterone, androgen antagonists, or androgen receptor pathway inhibitors. We defined adverse cardiovascular event as myocardial infarctions, heart failure, or strokes. Time to adverse cardiovascular event was defined using longitudinal electronic health record data. We evaluated whether HT use affected the risk of adverse cardiovascular events using a Cox regression model adjusted for established cardiovascular risk factors.</p><p><strong>Results: </strong>The final cohort included 5156 participants. After adjustment for cardiovascular risk covariates, HT treatment was associated with increased risk of adverse cardiovascular event (HR: 1.22; 95% CI: 1.01-1.48; p = 0.03). In participants with pre-treatment dyslipidemia, HT usage was associated with increased risk of adverse cardiovascular events (HR: 1.52; 95% CI: 1.19-1.95; p < 0.001). In participants without pre-treatment dyslipidemia, no association was found (HR: 0.96; 95% CI: 0.71-1.30; p = 0.81).</p><p><strong>Conclusions: </strong>Our results show that HT-associated cardiovascular risk may be synergistically amplified by dyslipidemia. These results suggest that risk stratification by dyslipidemia status may improve cardiovascular outcomes for prostate cancer survivors.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1077-1086"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}